KR20140033240A - 다발성 골수종의 치료를 위한 ｃｄ38에 대한 항체 - Google Patents

다발성 골수종의 치료를 위한 ｃｄ38에 대한 항체 Download PDF

Info

Publication number
KR20140033240A
KR20140033240A KR1020147004315A KR20147004315A KR20140033240A KR 20140033240 A KR20140033240 A KR 20140033240A KR 1020147004315 A KR1020147004315 A KR 1020147004315A KR 20147004315 A KR20147004315 A KR 20147004315A KR 20140033240 A KR20140033240 A KR 20140033240A
Authority
KR
South Korea
Prior art keywords
seq
human
antibody
sequence
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147004315A
Other languages
English (en)
Korean (ko)
Inventor
미켈드 비어스
이포 그라우스
주디쓰 오프린스
폴 파렌 파렌
얀 판 데 빈켈
마르틴 판 푸그트
Original Assignee
젠맵 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠맵 에이/에스 filed Critical 젠맵 에이/에스
Priority claimed from PCT/DK2006/000166 external-priority patent/WO2006099875A1/en
Publication of KR20140033240A publication Critical patent/KR20140033240A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020147004315A 2005-03-23 2006-03-23 다발성 골수종의 치료를 위한 ｃｄ38에 대한 항체 Ceased KR20140033240A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
DKPA200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US60/667,579 2005-04-01
US69616305P 2005-07-01 2005-07-01
US60/696,163 2005-07-01
US72856105P 2005-10-20 2005-10-20
US60/728,561 2005-10-20
PCT/DK2006/000166 WO2006099875A1 (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077024204A Division KR101433381B1 (ko) 2005-03-23 2006-03-23 다발성 골수종의 치료를 위한 ｃｄ38에 대한 항체

Publications (1)

Publication Number Publication Date
KR20140033240A true KR20140033240A (ko) 2014-03-17

Family

ID=50644285

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147004315A Ceased KR20140033240A (ko) 2005-03-23 2006-03-23 다발성 골수종의 치료를 위한 ｃｄ38에 대한 항체

Country Status (12)

Country Link
KR (1) KR20140033240A (enExample)
BE (1) BE2017C062I2 (enExample)
DK (1) DK1866338T3 (enExample)
ES (2) ES2644982T3 (enExample)
HU (2) HUE030783T2 (enExample)
LT (2) LT1866338T (enExample)
NZ (2) NZ625944A (enExample)
PL (1) PL1866338T3 (enExample)
PT (2) PT2567976T (enExample)
RS (1) RS55442B1 (enExample)
SG (1) SG10201610317VA (enExample)
UA (2) UA116520C2 (enExample)

Also Published As

Publication number Publication date
RS55442B1 (sr) 2017-04-28
LT1866338T (lt) 2017-01-25
ES2644982T3 (es) 2017-12-01
SG10201610317VA (en) 2017-02-27
PT2567976T (pt) 2017-10-19
UA116520C2 (uk) 2018-04-10
DK1866338T3 (da) 2017-01-02
HUE030783T2 (en) 2017-06-28
HUE034962T2 (en) 2018-03-28
PT1866338T (pt) 2016-12-14
UA98756C2 (ru) 2012-06-25
NZ625944A (en) 2016-01-29
ES2606762T3 (es) 2017-03-27
PL1866338T3 (pl) 2017-04-28
BE2017C062I2 (enExample) 2025-12-03
LT2567976T (lt) 2017-12-11
NZ600059A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
US20240228662A9 (en) Antibodies against cd38 for treatment of multiple myeloma
US20090076249A1 (en) Antibodies against CD38 for treatment of multiple myeloma
KR20140033240A (ko) 다발성 골수종의 치료를 위한 ｃｄ38에 대한 항체
HK1236545A1 (en) Antibodies against cd38 for treatment of multiple myeloma
HK1183047B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1107826B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1179979B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1183047A (en) Antibodies against cd38 for treatment of multiple myeloma
HK1179979A (en) Antibodies against cd38 for treatment of multiple myeloma

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140219

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140321

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140526

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140526

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I